
    
      Telostop TAB is fixed-dose combination of telmisartan and rosuvastatin, which was approved in
      2015 in the Republic of Korea for the treatment of patients with hypertention and
      dyslipidemia. A post-marketing surveillance was conducted following the approval to obtain
      data on the safety and efficacy of Telostop TAB in real-world practice.
    
  